Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: cubsfan who wrote (5292)	4/13/2009 9:00:55 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

DNDN rumor is that their stuff gets approved on or about APril 28. Massive squeeze and options trade like GNTA options before GNTA went belly up. For DNDN this is a make or break situation. Make = 30+, break = 0.10 thats also the danger of call options buying. No stock to short here, now. There are dissenting opinions on DNDN Message 25559156 then, dndn can not afford the slightest failure, as they disclosed stats when they shouldn´t have. The only other imaginable reason is that they have a big hand behind them...

To: cubsfan who wrote (5292)	4/13/2009 10:12:00 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

FAZ an unmitigated disaster. it will kiss FAS below 10... heli ben did it today; bought US treasuries out of the cave.

To: cubsfan who wrote (5292)	4/13/2009 7:31:14 PM
From: RockyBalboa	Respond to of 6370

Damn, DNDN scheduled the CC with investors for tomorrow. Some calendar spread holders are getting hosed as they hoped for a smooth expiry of the April series - not! reuters.com stock is currently halted UPDATE 1-Dendreon to unveil Provenge prostate cancer data Mon Apr 13, 2009 6:49pm EDT * Provenge data to be unveiled on Tuesday * Study aims to confirm positive results of earlier trial NEW YORK, April 13 (Reuters) - Dendreon Corp (DNDN.O) on Monday said it would hold a conference call with investors on Tuesday to discuss long-awaited results from a late-stage study of its Provenge treatment for prostate cancer. The biotechnology company declined late Monday to comment on findings from the two-year study, called IMPACT. The study includes more than 500 men with late-stage prostate cancer who have not benefited from drugs that sharply lower testosterone -- the male sex hormone which fuels progression of the cancer. Seattle-based Dendreon has said it aims to seek U.S. approval of the medicine soon afterward if the trial shows at least a 22 percent reduced risk of death, versus a placebo. An outside advisory panel of doctors in March 2007 recommended that the U.S. Food and Drug Administration approve Provenge, based on favorable efficacy and safety results from an earlier Phase III study study. But the FDA declined to approve the medicine -- a therapeutic vaccine containing traces of a protein linked to prostate cancer -- until data from the IMPACT study confirmed earlier trends. It would be the first approved cancer immunotherapy, meaning a drug to fight cancer by stimulating the immune system to attack cancer cells. Dendreon's shares closed up 16 percent at $7.30 Monday on Nasdaq. (Reporting by Ransdell Pierson; Editing Bernard Orr)